Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Daojun, Mo"'
Autor:
Janet E. Pope, Yvonne C. Lee, Jeffrey R. Curtis, Daojun Mo, Li Xie, Christina L. Dickson, Douglas E. Schlichting, Anabela Cardoso, Lee S. Simon, Peter C. Taylor
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 3, Pp 254-258 (2022)
Objective Pain reduction with baricitinib was assessed in patients with rheumatoid arthritis (RA) who either used opioids or did not use opioids during three randomized, double‐blind phase 3 trials. Methods Analysis populations were as follows: i)
Externí odkaz:
https://doaj.org/article/86a87bdaa02641a29f900d98f08520ca
Autor:
Genovese, Mark C *, Smolen, Josef S, Takeuchi, Tsutomu, Burmester, Gerd, Brinker, Dennis, Rooney, Terence P, Zhong, Jinglin, Daojun, Mo, Saifan, Chadi, Cardoso, Anabela, Issa, Maher, Wu, Wen-Shuo, Winthrop, Kevin L
Publikováno v:
In The Lancet Rheumatology June 2020 2(6):e347-e357
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roberto Caporali, Daniel Aletaha, Raimon Sanmartí, Tsutomu Takeuchi, Daojun Mo, Ewa Haladyj, Liliana Zaremba-Pechmann, Peter C Taylor
Publikováno v:
Rheumatology. 62
Background/Aims Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, has demonstrated efficacy in patients (pts) with rheumatoid arthritis (RA) for up to 3 years (yrs) in a long-term extension (LTE) study RA-BEYOND. This analysis reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be6d6d7f00ce67859f3767fbd9af9770
https://doi.org/10.1093/rheumatology/kead104.166
https://doi.org/10.1093/rheumatology/kead104.166
Autor:
Roberto Caporali, Daniel Aletaha, Raimon Sanmartí, Tsutomu Takeuchi, Daojun Mo, Ewa Haladyj, Liliana Zaremba-Pechmann, Peter C Taylor
Publikováno v:
Rheumatology. 62
Background/Aims Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy in patients (pts) with RA who have inadequa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7499b40ff2af1fed0574b05ff3ca3796
https://doi.org/10.1093/rheumatology/kead104.148
https://doi.org/10.1093/rheumatology/kead104.148
Autor:
Roy Fleischmann, Yoshiya Tanaka, Patrick Durez, Daojun Mo, Cynthia E. Kartman, Douglas E Schlichting, Li Xie, Scott Beattie, Désirée van der Heijde
Publikováno v:
The Journal of rheumatology, Vol. 49, no.2, p. 133-141 (2022)
ObjectiveTo evaluate the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active rheumatoid arthritis (RA).MethodsPatients completed 1 of 3 phase III baricitinib trials (ClinicalTri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eefacc495f67f5f6a823865792f34287
https://doi.org/10.3899/jrheum.210346
https://doi.org/10.3899/jrheum.210346
Autor:
Janet E. Pope, Yvonne C. Lee, Jeffrey R. Curtis, Daojun Mo, Li Xie, Christina L. Dickson, Douglas E. Schlichting, Anabela Cardoso, Lee S. Simon, Peter C. Taylor
Publikováno v:
ACR open rheumatology. 4(3)
Objective Pain reduction with baricitinib was assessed in patients with rheumatoid arthritis (RA) who either used opioids or did not use opioids during three randomized, double-blind phase 3 trials. Methods Analysis populations were as follows: i) ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eadc8affb6a0cbc82052e0f7b136df5
https://pubmed.ncbi.nlm.nih.gov/34913611
https://pubmed.ncbi.nlm.nih.gov/34913611
Autor:
C. Walls, Kevin L. Winthrop, Douglas E Schlichting, Gerd R Burmester, Daojun Mo, Josef S Smolen, Tsutomu Takeuchi, Walter Deberdt
Publikováno v:
Rheumatology. 60
Background/Aims Baricitinib (BARI) is an oral selective inhibitor of Janus kinase (JAK)1/2, approved for treatment of moderate-to-severe- rheumatoid arthritis (RA) in adults. Here, we update the drug’s safety profile with data up to 8.4 years of tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ce5ed1b01276c28e142b793d53e344d
https://doi.org/10.1093/rheumatology/keab246.008
https://doi.org/10.1093/rheumatology/keab246.008
Autor:
Dennis Brinker, Josef S Smolen, Daojun Mo, Jinglin Zhong, Tsutomu Takeuchi, Wen-Shuo Wu, Terence Rooney, Mark C. Genovese, Kevin L. Winthrop, Anabela Cardoso, Chadi Saifan, Gerd R Burmester, Maher Issa
Publikováno v:
Poster Presentations.
Background: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK 2, to treat moderately to severely active RA in adults. Objectives: To update bari’s safety profile with data from an additional Phase (Ph) 3 trial and on-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69fd2ee60fc42e496cf7eb69822c9803
https://doi.org/10.1136/annrheumdis-2019-eular.691
https://doi.org/10.1136/annrheumdis-2019-eular.691
Autor:
T. Takeuchi, C. Walls, Daojun Mo, Kevin L. Winthrop, H. Song, B. Combe, Mark C. Genovese, Josef S. Smolen, Walter Deberdt, Douglas E Schlichting, G.-R. Burmester
Publikováno v:
Revue du Rhumatisme. 87:A109
Introduction Baricitinib, un inhibiteur oral selectif des Janus Kinases (JAK)1/JAK2, indique dans le traitement de patients adultes atteints de polyarthrite rhumatoide (PR) active moderee a severe. Ce travail a eu comme objectif de decrire le profil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2ac3686e46b2231b2fead00c16bb754
https://doi.org/10.1016/j.rhum.2020.10.187
https://doi.org/10.1016/j.rhum.2020.10.187